Stoger, E.E.StogerSack, M.M.SackFischer, R.R.FischerChristou, P.P.Christou2022-03-032022-03-032002https://publica.fraunhofer.de/handle/publica/20191110.1016/S0958-1669(02)00303-8Various strategies have been developed to exploit plants as bioreactors for the production of pharmaceutical antibodies, to engineer antibody-mediated pathogen resistance or to alter the plant phenotype by immunomodulation. Recent research developments focus on the fine-tuning of expression systems and the detailed characterisation of recombinant products, including the implications of plant-specific glycosylation. Meanwhile, the first of these plant-derived antibody products has successfully completed early phase clinical trials.en570610620660journal article